Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NuGen Medical Devices Inc. (V:NGMD)

Business Focus: Medical Equipment, Supplies & Distribution (NEC)

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for NGMD within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 30, 2024 17:15 ET
NuGen Announces Completion of Product Training with Sol Millennium as European Markets Expand
Toronto, Ontario--(Newsfile Corp. - January 30, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that as of January 30th, 2024, Sol-Millennium Medical Inc.'s ("Sol-M") global sales & marketing team has now completed their in-depth clinical training of NuGen's needle-free InsuJet™ medical device for sales and marketing throughout Europe.
Read full article
Jan 19, 2024 17:15 ET
NuGen Receives Two Additional Sales Orders for InsuJet(TM) and Expands Distribution into Argentina, Chile, Costa Rica and Peru
Toronto, Ontario--(Newsfile Corp. - January 19, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to report that its distribution partner in Mexico, Science-Link Trading SAPI de CV ("Science-Link") has expanded their distribution network to now include Argentina, Chile, Costa Rica and Peru. Science-Link is now also partnering with a large family-owned laboratory and clinic conglomerate ("Conglomerate Medical") which is expected to see Science-Link expand its operations into big box retail pharmacies in Mexico. Mexico is a large diabetes market globally with an estimated 1 in 6 adults now living with diabetes[1].
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
127.10
4.23
3.45
Price to Book - most recent quarter
--
5.40
2.04
Price to Cash Flow per share - TTM
--
--
10.35
Price to Free Cash Flow per share - TTM
--
--
12.34
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 15, 2024842,492839,780
Feb 29, 20242,712-66,537
Feb 15, 202469,249-47,704
See Short Report

Business Summary

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution

NuGen Medical Devices Inc. is a Canada-based specialty medical device company. The Company is engaged in marketing and selling its InsuJet needle-free injection system designed to improve the lives of millions of diabetics. Its principal business is the research, development and commercialization of needle-free injection devices and systems for the administration of subcutaneous medication. It is developing products using its needle-free delivery technology in several fields including, but not limited to, diabetes, semaglutide, growth and fertility hormone, as well as deoxyribonucleic acid (DNA) and conventional/pediatric vaccines. It is focusing its development efforts on needle free devices in the area of liquid jet delivery through the InsuJet platform. The Company's InsuJet technology platform is based on jet-stream administration of liquid drugs. The Company manufactures and commercializes needle-free injection systems and sells in over 40 countries globally.

See business summary

 

Twitter

Search (past week) for $NGMD.CA NGMD.V

  • No tweets found